The dual contribution of SHP2 dysregulating tumor cell signals and inhibiting T cell function makes it a promising immuno-therapeutic target; for example, treatment of SHP2 inhibitor SHP099 was unchanged in tumor intrinsic model systems; however, it provided robust tumor burden reduction in immune composition mice through the induction of CD8+ T cell responses and increased expression of cytotoxic gene signatures. This evidence concerns the gene PTPN11 and neoplasm.